Understanding the Importance of Protein Activation in Cancer Therapy
The recent study adds significant insights into the growing body of evidence that emphasizes the measurement of activated proteins as a crucial factor in selecting effective cancer therapies.
Groundbreaking Research Published in a Renowned Journal
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ: BACK), has publicized a noteworthy study featured in the British Journal of Cancer. This research, focused on the functional activation of the AKT–mTOR signaling axis, highlights the vital role of directly measuring protein activation to effectively predict how patients will respond to targeted cancer treatments.
Precision Oncology Innovations
Led by Perthera in collaboration with the patient-centered Side-Out Foundation, the findings indicate that assessing protein activation offers a more reliable approach to anticipating therapeutic outcomes than relying solely on genomic profiling. Notably, the mutation status of tumors, identified through genomic analyses, did not align with protein activation levels and proved inadequate in forecasting patient responses.
Key Findings of the Study
This research provides several critical insights into the relationship between protein activation, genomic alterations, and therapeutic responses:
- Protein Activation as a Predictor: Patients showing functional activation of the AKT–mTOR signaling axis had significantly poorer responses to conventional first-line treatments utilizing CDK4/6 inhibitors.
- Disconnect Between Genomic and Protein Activity: The study uncovered a lack of correlation between genomic mutations—specifically in the PIK3CA, PTEN, or AKT genes—and the respective activation statuses of proteins in the pertinent pathway.
Enhancing Patient Outcomes Through Proteomics
Utilizing protein activation analysis has allowed for a more accurate identification of patients who are likely to benefit from endocrine therapy when combined with a CDK4/6 inhibitor. Dr. Mariaelena Pierobon, the senior author of the study, pointed out that this research illustrates the limitations associated with relying exclusively on genomic data when making treatment decisions. By directly assessing the activation states of proteins in the AKT–mTOR pathway, we can more effectively predict which patients may benefit from specific therapies.
Implications for Cancer Treatment and the AKT–mTOR Pathway
The AKT–mTOR pathway is critically involved in regulating cell growth, proliferation, and survival. Its dysregulation has been associated with various cancers, including metastatic breast cancer. Traditional genomic testing may frequently overlook the functional activation state of essential proteins, which can lead to suboptimal treatment choices.
Innovative Assay by Ignite Proteomics
- Direct Protein Measurement: Ignite Proteomics has developed an advanced Reverse Phase Protein Array (RPPA)-based assay that quantifies phosphorylation levels of proteins within the AKT–mTOR pathway.
- Emphasis on Functional Analysis: By concentrating on the functionality of proteins rather than only the presence of genetic mutations, the assay enables the formulation of actionable insights for more targeted treatment strategies.
Clinical Applications Highlighted
The study analyzed tumor samples from a cohort of metastatic breast cancer patients, revealing vital observations:
- Lack of Genomic to Proteomic Correlation: Genomic alterations did not predict protein activation levels or patient responses.
- Proteomic Insights on CDK4/6 Inhibitors: Patients with an activated AKT–mTOR signaling axis exhibited reduced responses to endocrine therapy combined with a CDK4/6 inhibitor, reflected by shorter progression-free survival.
- Personalizing Treatment: These findings advocate for integrating proteomic analyses in clinical practice to customize therapies based on functional protein behavior.
Justin Davis, PhD, Vice President of Research and Development at Ignite Proteomics, expressed confidence in their proteomic assay's ability to personalize cancer treatment: "By assessing the actual drivers of tumor behavior — the activated proteins — we empower clinicians with the knowledge necessary for making informed treatment decisions, thereby enhancing patient outcomes."
Strengthening Evidence in Cancer Treatment Assessment
This publication furthers the existing evidence indicating that measuring activated protein levels is critical for predicting responses, or lack thereof, to novel therapies.
Noteworthy Studies in the Field
A significant study from 2022, titled Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer, elaborated on similar findings, showing a strong association between activated AKT protein levels and improved clinical outcomes.
Empowering Precision Medicine with Ignite Proteomics
Ignite Proteomics uniquely offers a clinically validated assay that measures both the expression and activation levels of drug targets in breast cancer. This innovative approach not only empowers oncologists to choose the most effective therapies but also aligns with the unique proteomic profiles of individual tumors.
About Ignite Proteomics
Ignite Proteomics LLC is at the forefront of advanced cancer diagnostics, specializing in Reverse Phase Protein Array (RPPA) technology. Operating under a CLIA-accredited lab, Ignite Proteomics provides a comprehensive test that addresses multiple markers, helping physicians identify the most appropriate therapies while bridging gaps left by traditional gene-focused methods.
Learn More About IMAC Holdings, Inc.
IMAC Holdings, Inc. is dedicated to enhancing patient outcomes through innovative healthcare solutions. By strategically acquiring and integrating cutting-edge technologies, IMAC Holdings aims to advance personalized medicine initiatives. The company is in the process of rebranding to reflect its new identity as Ignite Sciences, Inc.
For More Information, Contact:
Email: Investors@imacholdings.com
Website: www.igniteproteomics.com
Frequently Asked Questions
What is the main focus of the published study from Ignite Proteomics?
The study emphasizes the importance of measuring protein activation to predict responses to breast cancer therapies.
Why is protein activation measurement considered superior to genomic profiling?
Protein activation measurement offers more accurate predictions for treatment responses than genomic profiling, which may not reflect functional protein status.
What role does the AKT–mTOR signaling pathway play in cancer?
This pathway is essential in regulating cell growth and survival, and its dysregulation is linked to various cancers.
How can Ignite Proteomics' assay benefit cancer treatment?
The assay helps oncologists select the most effective therapies based on the actual activity of proteins involved in cancer progression.
What is the future of precision medicine according to the findings?
The findings suggest that integrating proteomic analyses into clinical practice may lead to more personalized and effective cancer treatments.
